278 related articles for article (PubMed ID: 31584090)
1. New substituted quinoxalines inhibit triple-negative breast cancer by specifically downregulating the c-MYC transcription.
Hu MH; Wu TY; Huang Q; Jin G
Nucleic Acids Res; 2019 Nov; 47(20):10529-10542. PubMed ID: 31584090
[TBL] [Abstract][Full Text] [Related]
2. New Dibenzoquinoxalines Inhibit Triple-Negative Breast Cancer Growth by Dual Targeting of Topoisomerase 1 and the
Hu MH; Lin JH
J Med Chem; 2021 May; 64(10):6720-6729. PubMed ID: 33961424
[TBL] [Abstract][Full Text] [Related]
3. Non-fused imidazole-biphenyl analogs repress triple-negative breast cancer growth by mainly stabilizing the c-MYC G-quadruplex via a multi-site binding mode.
Wang XD; Wang JX; Yu BY; Zhang SQ; Hu MH
Bioorg Med Chem; 2023 Jun; 88-89():117336. PubMed ID: 37209638
[TBL] [Abstract][Full Text] [Related]
4. Discovery of a New Four-Leaf Clover-Like Ligand as a Potent c-MYC Transcription Inhibitor Specifically Targeting the Promoter G-Quadruplex.
Hu MH; Wang YQ; Yu ZY; Hu LN; Ou TM; Chen SB; Huang ZS; Tan JH
J Med Chem; 2018 Mar; 61(6):2447-2459. PubMed ID: 29474069
[TBL] [Abstract][Full Text] [Related]
5. SPAG5 upregulation contributes to enhanced c-MYC transcriptional activity via interaction with c-MYC binding protein in triple-negative breast cancer.
Li M; Li A; Zhou S; Lv H; Yang W
J Hematol Oncol; 2019 Feb; 12(1):14. PubMed ID: 30736840
[TBL] [Abstract][Full Text] [Related]
6. Design, Synthesis, and Evaluation of New Selective NM23-H2 Binders as c-MYC Transcription Inhibitors via Disruption of the NM23-H2/G-Quadruplex Interaction.
Wang YQ; Huang ZL; Chen SB; Wang CX; Shan C; Yin QK; Ou TM; Li D; Gu LQ; Tan JH; Huang ZS
J Med Chem; 2017 Aug; 60(16):6924-6941. PubMed ID: 28714689
[TBL] [Abstract][Full Text] [Related]
7. Syntheses and Evaluation of New Bisacridine Derivatives for Dual Binding of G-Quadruplex and i-Motif in Regulating Oncogene
Kuang G; Zhang M; Kang S; Hu D; Li X; Wei Z; Gong X; An LK; Huang ZS; Shu B; Li D
J Med Chem; 2020 Sep; 63(17):9136-9153. PubMed ID: 32787078
[TBL] [Abstract][Full Text] [Related]
8. A drug-like imidazole-benzothiazole conjugate inhibits malignant melanoma by stabilizing the c-MYC G-quadruplex.
Wu TY; Huang Q; Huang ZS; Hu MH; Tan JH
Bioorg Chem; 2020 Jun; 99():103866. PubMed ID: 32330737
[TBL] [Abstract][Full Text] [Related]
9. The Role and Mechanism of CRT0066101 as an Effective Drug for Treatment of Triple-Negative Breast Cancer.
Liu Y; Wang Y; Yu S; Zhou Y; Ma X; Su Q; An L; Wang F; Shi A; Zhang J; Chen L
Cell Physiol Biochem; 2019; 52(3):382-396. PubMed ID: 30845378
[TBL] [Abstract][Full Text] [Related]
10. Quinazoline derivative QPB-15e stabilizes the c-myc promoter G-quadruplex and inhibits tumor growth in vivo.
Li Z; Liu C; Huang C; Meng X; Zhang L; He J; Li J
Oncotarget; 2016 Jun; 7(23):34266-76. PubMed ID: 27144522
[TBL] [Abstract][Full Text] [Related]
11. Silibinin induces metabolic crisis in triple-negative breast cancer cells by modulating EGFR-MYC-TXNIP axis: potential therapeutic implications.
Iqbal MA; Chattopadhyay S; Siddiqui FA; Ur Rehman A; Siddiqui S; Prakasam G; Khan A; Sultana S; Bamezai RN
FEBS J; 2021 Jan; 288(2):471-485. PubMed ID: 32356386
[TBL] [Abstract][Full Text] [Related]
12. MYC Inhibition Depletes Cancer Stem-like Cells in Triple-Negative Breast Cancer.
Yang A; Qin S; Schulte BA; Ethier SP; Tew KD; Wang GY
Cancer Res; 2017 Dec; 77(23):6641-6650. PubMed ID: 28951456
[TBL] [Abstract][Full Text] [Related]
13. Piperine analogs arrest c-myc gene leading to downregulation of transcription for targeting cancer.
Pandya N; Kumar A
Sci Rep; 2021 Nov; 11(1):22909. PubMed ID: 34824301
[TBL] [Abstract][Full Text] [Related]
14. The bromodomain inhibitor OTX015 (MK-8628) exerts anti-tumor activity in triple-negative breast cancer models as single agent and in combination with everolimus.
Vázquez R; Riveiro ME; Astorgues-Xerri L; Odore E; Rezai K; Erba E; Panini N; Rinaldi A; Kwee I; Beltrame L; Bekradda M; Cvitkovic E; Bertoni F; Frapolli R; D'Incalci M
Oncotarget; 2017 Jan; 8(5):7598-7613. PubMed ID: 27935867
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of fatty acid oxidation as a therapy for MYC-overexpressing triple-negative breast cancer.
Camarda R; Zhou AY; Kohnz RA; Balakrishnan S; Mahieu C; Anderton B; Eyob H; Kajimura S; Tward A; Krings G; Nomura DK; Goga A
Nat Med; 2016 Apr; 22(4):427-32. PubMed ID: 26950360
[TBL] [Abstract][Full Text] [Related]
16. RB loss contributes to aggressive tumor phenotypes in MYC-driven triple negative breast cancer.
Knudsen ES; McClendon AK; Franco J; Ertel A; Fortina P; Witkiewicz AK
Cell Cycle; 2015; 14(1):109-22. PubMed ID: 25602521
[TBL] [Abstract][Full Text] [Related]
17. Drug-like biimidazole derivatives dually target c-MYC/BCL-2 G-quadruplexes and inhibit acute myeloid leukemia.
Hu MH; Yu BY; Wang X; Jin G
Bioorg Chem; 2020 Nov; 104():104264. PubMed ID: 32920366
[TBL] [Abstract][Full Text] [Related]
18. Design, Synthesis, and Evaluation of New Sugar-Substituted Imidazole Derivatives as Selective
Li ML; Yuan JM; Yuan H; Wu BH; Huang SL; Li QJ; Ou TM; Wang HG; Tan JH; Li D; Chen SB; Huang ZS
J Med Chem; 2022 Oct; 65(19):12675-12700. PubMed ID: 36121464
[No Abstract] [Full Text] [Related]
19. PIM1 kinase inhibition as a targeted therapy against triple-negative breast tumors with elevated MYC expression.
Horiuchi D; Camarda R; Zhou AY; Yau C; Momcilovic O; Balakrishnan S; Corella AN; Eyob H; Kessenbrock K; Lawson DA; Marsh LA; Anderton BN; Rohrberg J; Kunder R; Bazarov AV; Yaswen P; McManus MT; Rugo HS; Werb Z; Goga A
Nat Med; 2016 Nov; 22(11):1321-1329. PubMed ID: 27775705
[TBL] [Abstract][Full Text] [Related]
20. Design, synthesis, and validation of novel nitrogen-based chalcone analogs against triple negative breast cancer.
Elkhalifa D; Siddique AB; Qusa M; Cyprian FS; El Sayed K; Alali F; Al Moustafa AE; Khalil A
Eur J Med Chem; 2020 Feb; 187():111954. PubMed ID: 31838326
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
